Researchers from the National Cancer Research Center in Tokyo report in the current issue of Clinical Cancer Research that they have successfully used DxS' Amplified Refractory Mutation System technology to identify drug-sensitizing mutations in the epidermal growth factor receptor gene from DNA floating free in serum, a step that may foreshadow the use of molecular diagnostics to monitor patients' likely drug responses in non-small cell lung cancer, and by extension other cancers.